Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human antithrombin III for prevention of perioperative and peripartum venous thrombosis in congenital antithrombin III deficiency
CTR20232591Phase 3Completed
- Sponsor
- Shandong Taibang Biological Products
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of antithrombin III in congenital antithrombin deficiency (ATD) and venous thromboembolism (VTE), sponsored by Shandong Taibang Biological Products. Primary endpoint: Incidence of new venous thromboembolism events. Started Aug 2023; status: completed.
02
Drugs
antithrombin III
03
Conditions
congenital antithrombin deficiency (ATD)venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20232591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232591.